Browse studies

Find your next paid study

25 recruiting studies matching your filters

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommende…

Autoimmune DisordersSystemic SclerosisSystemic Lupus Erythematosus+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06434363